Table 2.
Clinical and pathological information of CESC patients.
| Clinical feature | Variable | Patients (%) |
|---|---|---|
| Age at diagnosis (years) | >60 | 59 (19.4) |
| ≤60 | 245 (80.6) | |
| Race | White | 209 (68.8) |
| Black or African American | 30 (9.87) | |
| Native Hawaiian or other Pacific islander | 2 (0.61) | |
| Asian | 20 (6.58) | |
| American Indian or Alaska native | 7 (2.3) | |
| Other | 36 (11.84) | |
| Clinical stage | Stage I | 162 (53.29) |
| Stage II | 69 (22.7) | |
| Stage III | 45 (14.8) | |
| Stage IV | 21 (6.91) | |
| Other | 7 (2.3) | |
| Neoplasm histologic grade | g1 | 18 (5.92) |
| g2 | 135 (44.41) | |
| g3 | 118 (38.82) | |
| g4 | 1 (0.33) | |
| gx | 24 (7.89) | |
| Other | 8 (2.63) | |
| HPV status | Indeterminate | 1 (0.33) |
| Negative | 22 (7.24) | |
| Positive | 281 (92.43) | |
| Menopause status | Pre (<6 months since lmp and no prior bilateral ovariectomy and not on estrogen replacement) | 124 (40.79) |
| Post (prior bilateral ovariectomy or >12 mo since lmp with no prior hysterectomy) | 82 (26.97) | |
| Peri (6–12 months since last menstrual period) | 25 (8.22) | |
| Indeterminate (neither pre or postmenopausal) | 3 (0.99) | |
| Other | 70 (23.03) | |
| Lymphovascular involvement | Absent | 71 (23.36) |
| Present | 79 (25.99) | |
| Other | 154 (50.65) | |
| Pathology T stage | T1 | 140 (46.05) |
| T2 | 71 (23.36) | |
| T3 | 20 (6.58) | |
| T4 | 10 (3.29) | |
| Tis | 1 (0.33) | |
| Tx | 17 (5.59) | |
| Other | 45 (14.8) | |
| Pathology N stage | N0 | 133 (43.75) |
| N1 | 60 (19.74) | |
| Nx | 66 (21.71) | |
| Other | 45 (14.8) | |
| Pathology M stage | M0 | 116 (38.16) |
| M1 | 10 (3.29) | |
| Mx | 128 (42.1) | |
| Other | 50 (16.45) |